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Medullary carcinoma is a rare malignant tumor of the kidney. It affects individuals of African descent and
all cases reported show evidence of sickle cell trait. We reviewed an unusual carcinoma arising in a white
man, the ninth in the literature. The tumor demonstrated features associated with renal medullary
carcinoma, or unclassiﬁed renal cell carcinoma, medullary phenotype as recently described; the presence
of sickle cell trait conﬁrmed the diagnosis of medullary carcinoma. This case is helpful in the differential
diagnosis with non-sickle cell associated “renal cell carcinoma, unclassiﬁed with medullary phenotype,”
and study of this spectrum of tumors is ongoing.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Renal medullary carcinoma (RMC) is a rare aggressive subtype of
renal tumor, with 182 cases reported in the English literature,1e5
originating from the medulla of the kidney and associated with
sickle cell trait and disease.1 The great majority of patients reported
have been African-Americans. Herein we describe the clinicopath-
ologic features of an RMC arising in a white man with sickle cell
trait. RMC has never been reported in Italy, highlighting the degree
of clinical suspicion necessary to identify such a case.Case presentation
A 23-year old white male presented with left-sided loin pain,
without hematuria. Ultrasound examination showed a renal mass.umanitas Research Hospital,
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Inc. This is an open access article uAbdominal computed tomography (CT) scan conﬁrmed the sono-
graphic ﬁndings demonstrating a 42 mmmass in the upper pole of
the left kidney, with enlargement of regional lymph-nodes. The
histology of CT-guided needle biopsy revealed necrotic tissue and
only a focus of viable neoplastic proliferation of atypical epithelial
cells, primarily compatible to renal cell carcinoma, not otherwise
speciﬁed. Subsequently patient underwent to a staging full body CT,
which revealed multiple bilateral lung metastases. Radical ne-
phrectomy with regional lymphadenectomy was performed. At
gross examination, the specimen revealed a yellowish-white mass
in the upper renal pole, 5.5 cm in diameter, with invasion of both
perirenal and renal sinus fat (Fig. 1A).
Histologically, the tumor showed proliferation of epithelioid
cells, arranged in tubular and cribriform structures, in desmoplastic
and myxoid stroma (Fig. 1B). There were multiple foci of necrosis
(w40% of the tumor), and a rich acute inﬂammatory inﬁltrate
(Fig. 1C). There was also a massive metastasis in one hilar lymph
node. Drepanocytes (sickle forms) were histologically noted, and
taken with the tumor morphologic characteristics, tests were or-
dered to screen for hemoglobinopathies (Fig. 1D). A peripheral
blood hemoglobin electrophoresis, performed in the Clinicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Gross and microscopic characteristics of the tumor and sickle cell status (AeE). A, Note that the tumor is located in the cortico-medullary region, with lymph node hilar
metastasis. B and C, Glandular differentiation and desmoplastic stroma with inﬂammatory cells in the medullary carcinoma. D, Drepanocytes identiﬁed between and at the pe-
riphery of the carcinoma. E, Electrophoretic analysis documented high level of mutated Hemoglobin (S).
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histological suspicion (Fig. 1E).
Given the rarity of this tumor in Caucasians, extensive immu-
nohistochemical studies were performed, showing reactivity for
cytokeratins, polyclonal CEA, PAX8, PAX2, AMACR, S100A1, and
OCT3/4. An immunostain for the chromatin-modifying protein
SMARCB1 (also known as INI-1) was negative (Fig. 2). In the light of
these ﬁndings taken together, a diagnosis of RMC was made.Disease progressed, under treatment with Sunitinib and Sor-
afenib, and the patient died at 10 months of follow-up with mul-
tiple pulmonary metastases.
Discussion
Since the original studies by Davis et al, 182 cases of renal RMC
have been reported, and the great majority in African-American
Figure 2. Immunohistochemical status in medullary carcinoma (AeF). Tumor cells are diffusely positive for CK AE1/AE3 (A), S100A1 (B), PAX2 (C), and focally positive for OCT3/4
(D). No expression for INI1 (E) and GATA3 (F) is evident.
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nature of the case presented concerns the tumor arising in a white
male without apparent genealogic link to African or American
populations, as well as the unusual laterality of disease, in the left
kidney. To the best of our knowledge, this is the ﬁrst Italian case of
RMC reported in the English literature.
RMC usually presents with hematuria, pain, weight loss, and
fever; our patient had left-sided loin pain, without hematuria,
conﬁrming that RMC bleeding is more typical for right sided tu-
mors.1 Though CT scan is the imaging modality of choice for RMC,
both ultrasound and abdominal CT scan performed identiﬁed the
mass. Importantly, when a core biopsy was performed, only
necrotic material with a focus of neoplastic tissue was obtained,
limiting histological diagnosis to renal cell carcinoma without the
possibility of further classiﬁcation.
The mean RMC size is 7 cm (1.8 to 13).1,2 The most consistent
histological pattern described in the literature includes anasto-
mosing tubules and cords forming microcystic structures with
reticular appearance; less frequently with cribriform, solid, micro-
papillary, and rhabdoid morphologies, associated with a desmo-
plastic stromal reaction. A brisk inﬂammatory component is often
seen, and intraluminal mucin is frequently documented (w70% of
cases). The overall most prevalent tumor that can simulate RMC is
high grade urothelial carcinoma of the pelvicalyceal mucosa with
glandular differentiation. Fortunately, urothelial carcinoma is often
associated to dysplastic change, or carcinoma in situ (CIS) in the
residual adjacent mucosa. The expression of SMARCB1 is quite
helpful to support diagnosis of urothelial carcinoma. Similarly,metastatic deposits of adenocarcinoma in the renal parenchyma
from other organs may also be quite challenging in the differential
diagnosis. Reviewing the literature, a principal area of concern has
been the overlapping clinicopathologic features between RMC and
collecting duct carcinoma (CDC), given that both demonstrate male
predominance, aggressive clinical course with high stage at pre-
sentation, prevalent right-sided disease, and intratumoral desmo-
plastic and inﬂammatory reactions.2 RMC has been considered
distinct from CDC in that it is documented in a younger population
than CDC (mean age 19 years versus 50 years in CDC) with a male to
female ratio of 2:1; furthermore, all patients have sickle cell trait or
disease (0% in CDC) and more than 90% are African-Americans (10%
in CDC).1
Recently, absence of SMARCB1/INI-1 protein expression has
been demonstrated in RMC by immunohistochemistry and loss of
heterozygosity of the SMARCB1 gene by microsatellite analysis.4
SMARCB1 is a tumor suppressor gene located on chromosome 22,
involved in cell cycle control and regulation of the cytoskeleton.
Immunohistochemistry of the current case showed absence of
nuclear staining of SMARCB1 (Fig. 2). Recently, some authors have
documented that OCT3/4, a sensitive and speciﬁc marker for germ-
cell tumors, was expressed in 10/14 RMC analyzed, as in our case,
underlining the potential diagnostic pitfall with using it, particu-
larly when a clear history of sickle cell trait is not available.
This particular conundrum, the CDC versus RMC differential, has
been the subject of a recent editorial, written by two of the authors
(MBA, SCS) in consultation with an international panel of kidney
experts.5With increasing use of allegedly “speciﬁc”markers such as
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convincing features of medullary carcinoma in individuals where
sickle cell trait has been rigorously excluded. The term “renal cell
carcinoma, unclassiﬁed, with medullary phenotype” (RCCU-MP)
has been proposed to provide terminology for such cases, with the
recommendation that the criteria used to make that designation
and clinical data used in exclusion of sickle cell trait (and therefore
diagnosis of RMC) be recorded in the pathologist’s comment.
Conclusion
We emphasize to consider a broad differential diagnosis with
careful clinical and laboratory correlation to secure the correct
diagnosis even in the rarest of circumstances. We hence recom-
mend availing of the latest published literature in this rapidly
evolving area of kidney pathology, hoping that emerging technol-
ogies and understandingwill make a better diagnosis, classiﬁcation,
and treatment. Additional study is needed to understand the rela-
tionship between CDC, RMC and RCCU-MP and to characterize, andhopefully identify targets within, the molecular circuitry leading to
the pathogenesis of these diseases.
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